Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UKMHRA grants approval for Kopran Ltd's facility in Savroli, Khalapur


Wednesday, 2 Apr 2014 05:43am EDT 

Kopran Ltd:Says United Kingdom, Medicines and Healthcare products Regulatory Agency (UKMHRA) has granted the Certificate of Compliance with principles and guidelines of Good Manufacturing Practice.Says for the Finished Dosage Forms facility located at Savroli, Khalapur, Khopoli manufacturing general capsules arid tablets.Says the approval for this facility shall enable the company to supply Finished Dosage Forms to the UK and the European market.Says the facility also has approvals from Regulatory Authorities of several countries all over the world including the Medicines Control Council, South Africa (MCC) and the Therapeutic Goods Administration, Australia (TGA). 

Company Quote

57.9
0.1 +0.17%
17 Apr 2015